Suprasellar Desmoplastic Infantile Ganglioglioma in a 7‐Month‐Old Infant: A Rare Diagnostic Consideration in Infant Suprasellar Masses Authors: Tawfiq Zuhair Abdullah Allaylah Published: 2026 ABSTRACT ABSTRACTDesmoplastic infantile ganglioglioma should be considered when an infant presents with a suprasellar mass, nystagmus, and developmental delay. Deep midline location limits resection, so BRAF V600E testing matters: it can open a targeted treatment option when surgery cannot control the disease.Keywords: brain neoplasms, ganglioglioma, immunohistochemistry, infant, proto‐oncogene proteins B‐raf, sella turcica Introduction Desmoplastic infantile ganglioglioma (DIG) and desmoplastic infantile astrocytoma (DIA) are rare neuroepithelial neoplasms that together account for roughly 0.4% of primary brain tumors and between 1.3% and 15.8% of tumors arising in infancy [1, 2, 3, 4]. Both are grouped as a single entity in the fifth edition of the World Health Organization (WHO) classification, designated CNS WHO Grade 1, and share a dominant desmoplastic leptomeningeal component; the presence of a neoplastic neuronal population distinguishes DIG from DIA [1, 2]. Most patients present before 24 months of age with macrocephaly, a bulging fontanelle, seizures, or raised intracranial pressure, and the classic lesion is a bulky superficial hemispheric mass with an enhancing nodule, one or more large cysts, and frequent dural attachment [4, 5]. Despite an alarming radiological appearance, prognosis after gross total resection is excellent [6]. Lesions arising outside the cerebral hemispheres are distinctly uncommon, and the suprasellar region is among the rarest sites. Only 18 suprasellar cases have been assembled in the largest pooled analysis, and the fifth‐edition WHO criteria note that extra‐hemispheric examples have generally not been confirmed genetically [2, 7]. This matters clinically because the imaging phenotype differs—suprasellar tumors are predominantly solid and rarely suggest DIG preoperatively—and because reported outcomes are considerably worse, with adherence to the optic apparatus, hypothalamus, and perforating vessels precluding complete excision [5, 7, 8]. A further consideration is that desmoplastic infantile tumors are driven by MAPK pathway activation, and a substantial minority carry the BRAF p.V600E substitution [2, 9]. Since dabrafenib combined with trametinib was shown to outperform carboplatin and vincristine as first‐line treatment of pediatric low‐grade glioma with BRAF V600 mutations, identifying that mutation in a child whose tumor cannot be resected has become a therapeutic decision [10]. We report a suprasellar DIG in a 7‐month‐old girl in whom mutation‐specific immunohistochemistry demonstrated BRAF V600E‐mutant protein, and in whom a positive result subsequently guided management when leptomeningeal dissemination was suspected. Case Presentation Clinical History and Examination A 7‐month‐old girl was referred to the neurosurgical service with a 2‐month history of persistent nystagmus and parental concern about delayed motor milestones. There had been no vomiting, seizures, irritability, or febrile illness, and no abnormality of visual behavior had been noticed before the nystagmus. She was born at term after an uncomplicated pregnancy and delivery, and there was no family history of neurological disease, neurocutaneous syndrome, or childhood malignancy. On examination, the occipitofrontal head circumference was 46 cm, corresponding to approximately the 90th percentile for age; serial measurements did not demonstrate the rapidly enlarging head circumference that typifies hemispheric disease. The anterior fontanelle was soft and not bulging. She was unable to sit unsupported, indicating gross motor delay for age. Ocular examination showed left‐beating gaze‐evoked nystagmus without ptosis, strabismus, or other cranial nerve deficit. Tone, power, and deep tendon reflexes were symmetrical and there was no hemiparesis. The remainder of the general and systemic examination was unremarkable, and there were no clinical features of diabetes insipidus, precocious puberty, diencephalic syndrome, or other hypothalamic–pituitary dysfunction at presentation. Radiological Findings Non‐contrast cranial CT demonstrated a heterogeneous 2.9 cm mass centered on the suprasellar region, with focal hyperattenuating areas consistent with dystrophic calcification and a large well‐defined cystic component of near‐CSF attenuation posterolaterally on the right (Figure 1). The lesion extended posteriorly along the optic tracts toward the right basal ganglia and thalamus. The lateral ventricles were not dilated. Axial CT scan showing a heterogeneous suprasellar mass extending posteriorly. The mass measures 2.9 cm in maximum diameter and involves the optic tracts, midbrain, right basal ganglia, and right thalamus. The lesion demonstrates mixed density with areas of hypodensity and hyperdensity. MRI confirmed a complex solid‐cystic lesion (Figure 2). The solid component was isointense to gray matter on T1‐weighted sequences and hyperintense on T2/FLAIR, with avid heterogeneous gadolinium enhancement. The cystic component was of near‐CSF signal without enhancement. The tumor was intimately related to the optic chiasm anteriorly, the pituitary stalk and hypothalamus superiorly, and the floor of the third ventricle, which was effaced and distorted; posterior extension involved the right thalamus and midbrain. There was no hydrocephalus, hemorrhage, diffusion restriction, or leptomeningeal enhancement at diagnosis. The combination of a deep midline epicenter, mixed solid‐cystic architecture, avid enhancement, and extension along the optic tracts placed craniopharyngioma, pilocytic astrocytoma, hypothalamic‐chiasmatic glioma, and germinoma at the top of the preoperative differential; DIG was not considered until histology was available. Axial FLAIR MRI sequence demonstrating the mixed solid and cystic components of the tumor. The image shows hyperintense signal in the suprasellar region with extension to adjacent structures. The lesion causes mass effect on surrounding brain parenchyma. Surgical Procedure A right pterional craniotomy with a trans‐sylvian approach was performed. The tumor was firm, grayish‐white and rubbery, was densely adherent to the optic chiasm and the floor of the third ventricle, and derived a rich blood supply from surrounding perforating vessels. Because of this adherence to the optic apparatus, hypothalamus, and adjacent vasculature, only partial resection was achieved: the cyst was decompressed and the accessible solid component debulked, and dissection was deliberately abandoned where the plane with the chiasm and hypothalamus could not be developed safely. There was no dural attachment and no leptomeningeal nodularity at any point in the exposure. Pathological Findings Intraoperative assessment showed a cellular, biphasic‐appearing neoplasm, and raised the possibility of a spindle‐cell lesion; definitive interpretation was appropriately deferred to permanent sections. This experience mirrors the recognized tendency of desmoplastic infantile tumors to be overgraded on squash preparations and mistaken for an infiltrating glioma because the desmoplasia yields scant, spindled, and worrying‐looking material [4, 5]. Formalin‐fixed, paraffin‐embedded sections stained with hematoxylin and eosin (H&E) showed the biphasic architecture that defines the entity (Figures 3 and 4). A dominant desmoplastic component composed of dense eosinophilic collagen bundles was arranged in interlacing fascicles and short storiform streams. Embedded within this matrix were spindled to ovoid neoplastic cells with elongated, mildly hyperchromatic nuclei, and inconspicuous nucleoli, together with a minor population of smaller, darker cells. Scattered larger cells with vesicular nuclei, visible nucleoli, and modest eosinophilic cytoplasm were identified and interpreted as ganglioid or immature ganglion cells (Figure 5); these were sparse and focal rather than conspicuous, and unequivocal fully mature dysmorphic ganglion cells with abundant Nissl substance were not seen. Mitotic figures were not identified. There was no necrosis, no glomeruloid microvascular proliferation, no perivascular chronic inflammatory infiltrate, and no xanthomatous change. A poorly differentiated, embryonal‐like small cell component of the type described in a proportion of desmoplastic infantile tumors was not represented in the submitted material. Low‐power microscopic view of the tumor smear preparation showing a desmoplastic pattern with spindle‐shaped cells arranged in fascicles. H&E stain demonstrates the characteristic fibrous stroma with interspersed neoplastic cells. High‐power microscopic view showing the characteristic arrangement of neoplastic cells within the desmoplastic stroma. The image demonstrates streams of cells within the collagenous matrix, a hallmark histological feature of desmoplastic infantile ganglioglioma. A reticulin impregnation demonstrated an abundant argyrophilic meshwork investing individual cells and small cell groups in a pericellular pattern, confirming the extensive basal‐lamina‐rich desmoplastic stroma (Figure 6). Reticulin special stain highlighting the desmoplastic component of the tumor with a characteristic pericellular pattern. This demonstrates the abundant collagen deposition that is typical of desmoplastic infantile ganglioglioma. The immunohistochemical panel, together with the clone, vendor, dilution, antigen retrieval protocol, and detection platform for every antibody applied and the controls used, is set out in Table 1. All immunohistochemistry was performed on an automated platform in an accredited reference laboratory (King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia). The glial component showed strong, diffuse cytoplasmic, and process labeling for glial fibrillary acidic protein (GFAP) (Figure 7) and strong nuclear and cytoplasmic labeling for S100 protein (Figure 8), and OLIG2 was expressed in the nuclei of the spindled population. Synaptophysin labeling was weak to moderate, patchy, and confined to scattered cells and a delicate neuropil‐like background rather than being strong and diffuse (Figure 9); we regard this as supportive of, rather than conclusive proof of, a neoplastic neuronal element. Neuronal nuclear antigen (NeuN), neurofilament protein, and chromogranin A were negative in the lesional cells. INI1 (SMARCB1) and ATRX nuclear expression were retained, p53 showed no aberrant accumulation, and epithelial membrane antigen (EMA) and pan‐cytokeratin were negative. Two separate histone‐related assays were performed and are reported separately to avoid ambiguity: nuclear expression of trimethylated histone H3 at lysine 27 (H3K27me3) was lost, whereas immunohistochemistry for the H3 K27M mutant protein was negative. The Ki‐67 labeling index was very low, with only isolated positive nuclei and an estimated index below 2% (Figure 10). TABLE 1Antibodies, histochemical stains, and molecular assays applied, with results in the present case.Antibody or stainCloneVendor (catalog no.)DilutionRetrievalResult in this caseBRAF V600EVE1 (mouse monoclonal)Ventana/Roche Tissue Diagnostics (760‐5095)Prediluted, ready to useCC1, 64 minPositive: convincing granular cytoplasmic labeling of the neoplastic fascicles and ganglioid cells; intervening desmoplastic collagen unstained (Figure 11)GFAPEP672Y (rabbit monoclonal)Cell Marque/Roche (05269784001; Cell Marque 1963)Prediluted, ready to useCC1, 32 minPositive: strong, diffuse cytoplasmic, and process labeling of the glial componentS100 proteinPolyclonal rabbitVentana/Roche (760‐2523)Prediluted, ready to useCC1, 32 minPositive: strong nuclear and cytoplasmic labelingOLIG2Polyclonal rabbitCell Marque (387A‐74)1:100CC1, 32 minPositive: nuclear labeling of the spindled neuroepithelial populationSynaptophysinSP11 (rabbit monoclonal)Ventana/Cell Marque (790‐4407)Prediluted, ready to useCC1, 32 minFocally positive: weak to moderate patchy cytoplasmic and neuropil‐like labelingNeuronal nuclear antigen (NeuN)A60 (mouse monoclonal)Merck Millipore (MAB377)1:200CC1, 32 minNegative in lesional cellsNeurofilament protein2F11 (mouse monoclonal)Ventana/Roche (760‐2680)Prediluted, ready to useCC1, 32 minNegative in lesional cellsChromogranin ALK2H10 (mouse monoclonal)Ventana/Roche (760‐2519)Prediluted, ready to useCC1, 32 minNegative in lesional cellsKi‐6730‐9 (rabbit monoclonal), CONFIRMVentana/Roche (790‐4286)Prediluted, ready to useCC1, 32 minLabeling index below 2% (isolated positive nuclei)INI1 (SMARCB1)MRQ‐27 (mouse monoclonal)Cell Marque (327M‐96)Prediluted, ready to useCC1, 32 minRetained nuclear expressionATRXPolyclonal rabbitCell Marque/Roche1:100CC1, 64 minRetained nuclear expressionp53DO‐7 (mouse monoclonal)Ventana/Roche (800‐2912)Prediluted, ready to useCC1, 32 minNo aberrant nuclear accumulationTrimethylated histone H3 at lysine 27 (H3K27me3)C36B11 (rabbit monoclonal)Cell Signaling Technology (9733)1:200CC1, 32 minNuclear expression lost (non‐neoplastic internal control nuclei positive)Histone H3 K27M mutant proteinRM192 (rabbit monoclonal)Cell Marque (492R‐14 concentrate)1:100CC1, 32 minNegative: no mutant protein expressionEpithelial membrane antigenE29 (mouse monoclonal)Ventana/Roche (760‐2610)Prediluted, ready to useCC1, 32 minNegativePan‐cytokeratinAE1/AE3 and PCK26Ventana/Roche (760‐2135)Prediluted, ready to useProtease 1NegativeReticulin (Gordon and Sweet silver impregnation)Not applicableNot applicableNot applicableNot applicableAbundant pericellular argyrophilic meshwork (Figure 6)Sequencing‐based molecular testing (BRAF and RAF1 sequencing, RNA fusion panel, DNA methylation profiling)Not applicableNot applicableNot applicableNot applicableNot performed; see Section 2.6 Note: All immunohistochemistry was performed at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia, on a Ventana BenchMark ULTRA automated platform (Roche Tissue Diagnostics, Tucson, AZ, USA) using OptiView or ultraView Universal DAB detection with hematoxylin counterstain. Unless otherwise indicated, heat‐induced epitope retrieval was carried out with Cell Conditioning Solution 1 (CC1, EDTA‐Tris, pH 8.4). Appropriate positive and negative external controls were run with each batch, and internal controls were assessed wherever available: entrapped normal brain and reactive astrocytes for GFAP and S100 protein; residual neuropil and normal neurons for synaptophysin and NeuN; non‐neoplastic nuclei for INI1, ATRX, and H3K27me3; and endothelial and inflammatory nuclei for Ki‐67. Preserved nuclear staining in non‐neoplastic cells was confirmed before H3K27me3 loss was accepted as genuine rather than technical. For BRAF V600E, a known p.V600E‐mutant tumor served as the external positive control, and the unstained desmoplastic collagen within the same section provided an internal negative control.Abbreviations: ATRX, alpha‐thalassemia/mental retardation syndrome X‐linked; CC1, cell conditioning solution 1; GFAP, glial fibrillary acidic protein; H3K27me3, trimethylated histone H3 at lysine 27; INI1, integrase interactor 1; OLIG2, oligodendrocyte transcription factor 2. Antibodies, histochemical stains, and molecular assays applied, with results in the present case. Note: All immunohistochemistry was performed at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia, on a Ventana BenchMark ULTRA automated platform (Roche Tissue Diagnostics, Tucson, AZ, USA) using OptiView or ultraView Universal DAB detection with hematoxylin counterstain. Unless otherwise indicated, heat‐induced epitope retrieval was carried out with Cell Conditioning Solution 1 (CC1, EDTA‐Tris, pH 8.4). Appropriate positive and negative external controls were run with each batch, and internal controls were assessed wherever available: entrapped normal brain and reactive astrocytes for GFAP and S100 protein; residual neuropil and normal neurons for synaptophysin and NeuN; non‐neoplastic nuclei for INI1, ATRX, and H3K27me3; and endothelial and inflammatory nuclei for Ki‐67. Preserved nuclear staining in non‐neoplastic cells was confirmed before H3K27me3 loss was accepted as genuine rather than technical. For BRAF V600E, a known p.V600E‐mutant tumor served as the external positive control, and the unstained desmoplastic collagen within the same section provided an internal negative control. Abbreviations: ATRX, alpha‐thalassemia/mental retardation syndrome X‐linked; CC1, cell conditioning solution 1; GFAP, glial fibrillary acidic protein; H3K27me3, trimethylated histone H3 at lysine 27; INI1, integrase interactor 1; OLIG2, oligodendrocyte transcription factor 2. Immunohistochemical staining for glial fibrillary acidic protein (GFAP) demonstrating cytoplasmic positivity in the glial component of the tumor. This confirms the astrocytic differentiation within the neoplasm. Immunohistochemical staining for S100 protein showing strong nuclear and cytoplasmic positivity in the neoplastic cells. This finding supports the glial component of the tumor and is characteristic of desmoplastic infantile ganglioglioma. Immunohistochemical staining for synaptophysin showing cytoplasmic positivity in the neuronal component of the tumor. This confirms the presence of neuronal differentiation, a key diagnostic feature of desmoplastic infantile ganglioglioma. Immunohistochemical staining for Ki‐67 showing a low proliferation index (< 2%), consistent with the generally indolent biological behavior of desmoplastic infantile ganglioglioma. Immunohistochemistry with the mutation‐specific antibody to BRAF p.V600E (clone VE1) showed convincing granular cytoplasmic expression of mutant protein (Figure 11). The distribution was informative in itself: labeling followed the neoplastic fascicles and the ganglioid cells within them, while the intervening bands of desmoplastic collagen remained entirely unstained. The unstained stroma therefore functioned as an internal negative control within the same field, and the pattern reproduces the compartmental distribution of mutant protein previously described in this entity, in which expression is confined to the tumor cell population and the leptomeningeal desmoplastic component is predominantly negative [11]. BRAF V600E immunohistochemistry (clone VE1). Strong granular cytoplasmic expression of mutant protein in the neoplastic cells within the desmoplastic matrix; the intervening collagenous stroma is unstained and provides an internal negative control. Diagnostic Reasoning and Differential Diagnosis The essential fifth‐edition WHO criterion for DIG or DIA is a desmoplastic neuroepithelial tumor arising in infancy with a leptomeningeal component, and this was met: the patient was 7 months old, the tumor had a dominant desmoplastic stroma with reticulin‐rich pericellular matrix, and GFAP‐positive spindled cells were the predominant population. Assignment as DIG rather than DIA requires a convincing neoplastic neuronal component. The evidence in this case is focal synaptophysin labeling in scattered cells with ganglioid morphology. NeuN, neurofilament protein, and chromogranin A were negative, and fully mature dysmorphic ganglion cells were not identified. We therefore acknowledge that DIA with ganglion‐like elements cannot be excluded from this partial specimen, but note that the distinction carries no current management consequence since both are CNS WHO Grade 1 and treated identically. The principal differential diagnoses were excluded as follows. Craniopharyngioma was excluded by the absence of squamous epithelium, wet keratin, and CTNNB1 nuclear expression. Pilocytic astrocytoma was excluded by the absence of biphasic architecture, Rosenthal fibers, and eosinophilic granular bodies, and by the prominent desmoplasia. Germinoma was excluded by the absence of large vesicular cells, lymphocytic infiltrate, and PLAP positivity. Infant‐type hemispheric glioma with NTRK or ALK fusion was excluded by the absence of the characteristic nodular architecture and by the BRAF V600E result, which is not a feature of that entity [12]. Diffuse midline glioma was excluded by the absence of H3 K27M mutant protein expression and by the Grade 1 morphology. Molecular Interpretation and Its Limitations Desmoplastic infantile tumors are driven by MAPK pathway activation, most often through BRAF p.V600E [2, 9]. Immunohistochemistry with clone VE1 showed convincing granular cytoplasmic expression of mutant protein in the neoplastic fascicles and ganglioid cells, while the intervening desmoplastic collagen was unstained (Figure 11). This compartmental pattern, with expression restricted to the tumor cell population and sparing of the stroma, reproduces the distribution described by Koelsche et al. in the only dedicated VE1 study of this entity, where the unstained stroma provided an internal negative control [11]. A positive result at this site is uncommon: VE1 was positive in only 3/18 tumors in that series, and all three Mayo Clinic suprasellar cases were VE1‐negative [8, 11]. VE1 is a surrogate for genotype and cannot detect non‐V600E substitutions or BRAF fusions; sequence‐level confirmation was not available. H3K27me3 expression was lost in the neoplastic cells, a finding reported in a subset of desmoplastic infantile tumors and distinct from H3 K27M mutant protein, which was negative, excluding diffuse midline glioma. Postoperative Course, Adjuvant Therapy, and Follow‐Up The immediate postoperative course was uncomplicated, without new visual deterioration, diabetes insipidus, electrolyte disturbance, seizures, or need for CSF diversion. Baseline pituitary and ophthalmological assessments were normal. Following partial resection, the case was reviewed at a multidisciplinary pediatric neuro‐oncology meeting, and neuraxis MRI at 6 weeks provided a surveillance baseline. Serial gadolinium‐enhanced MRI showed stable residual suprasellar tumor without interval growth. New leptomeningeal enhancement, including in the pre‐pontine cistern, was radiologically suspicious for cerebrospinal fluid dissemination. As no leptomeningeal enhancement was present preoperatively or on early postoperative MRI, this was an interval change. Cerebrospinal fluid cytology was not obtained; dissemination therefore remains suspected rather than proven. The combination of an unresectable residual tumor and new leptomeningeal disease was interpreted as disease activity beyond the original tumor bed and taken as an indication for systemic therapy, and the demonstration of BRAF V600E‐mutant protein on the resection specimen directly determined its choice. After multidisciplinary discussion and with written informed parental consent, combined MAPK pathway inhibition was commenced using dabrafenib 5.25 mg/kg/day, given as an oral suspension in two divided doses, together with trametinib 0.032 mg/kg once daily, the weight‐based pediatric doses established for children under 12 and under 6 years of age respectively [10, 13]. Conventional cytotoxic chemotherapy with carboplatin and vincristine was given concurrently, reflecting both the extent of leptomeningeal involvement and the absence of published experience with targeted therapy alone in disseminated desmoplastic infantile tumors. The approved pediatric indication for dabrafenib with trametinib in low‐grade glioma begins at 1 year of age; treatment in this patient was therefore initiated off‐label, on the basis of the molecular result and the absence of an effective alternative, after formal multidisciplinary review and with explicit parental consent. Monitoring for the recognized toxicities of this combination, including pyrexia, rash, diarrhea, and cardiac and ophthalmological adverse effects, was undertaken according to institutional protocol, and growth and development were assessed at each visit. At the most recent review, 4 months after surgery, the child was alive and continuing on combined targeted and cytotoxic therapy, which had been tolerated without dose‐limiting toxicity. The suprasellar residuum showed no interval growth, and the leptomeningeal and pre‐pontine enhancement was unchanged in extent, indicating radiological stability of the disseminated component on treatment rather than demonstrable regression. Nystagmus persisted but had not progressed; visual behavior was preserved to the extent assessable at this age, anterior and posterior pituitary function remained intact with normal growth velocity and no diabetes insipidus, and gross motor development continued to lag behind age expectation, for which she remains in a structured early intervention program. Clinical, ophthalmological, endocrine, and radiological review continues at three‐monthly intervals, with whole‐neuraxis imaging incorporated into surveillance because of the suspicion of cerebrospinal fluid dissemination. The follow‐up interval remains short, and no conclusion can yet be drawn about the durability of disease control. Discussion Three features make this case instructive: the location, the pathological argument achievable from a small deep specimen, and the way a single immunohistochemical result changed management once surgery had reached its limit. The clinical presentation reflected the anatomy. Hemispheric DIG/DIA characteristically declares itself through macrocephaly, a bulging fontanelle, or seizures [4, 5]. Our patient had neither hydrocephalus nor raised intracranial pressure; her presenting features—nystagmus and motor delay—reflected compression of the visual pathways and deep midline structures. This distinction matters because atypical symptoms may delay consideration of DIG in the differential. Radiologically, the present case is a partial exception to the reported suprasellar phenotype. Most published suprasellar cases have been predominantly solid and homogeneously enhancing, whereas our tumor retained the mixed solid‐cystic architecture more typical of hemispheric disease [5, 7]. That overlap did not resolve the preoperative differential, and DIG was not considered until histology was available, consistent with every previously reported suprasellar case. Surgically, the constraint we encountered is the rule. Radical removal has never been achieved in any published suprasellar case, and incomplete resection is the expected outcome [5, 7, 8]. This is the most important practical difference between suprasellar and hemispheric disease, and it is the reason BRAF testing has become therapeutically consequential at this site. The subsequent course illustrates why. Surveillance imaging showed stable residual tumor but new leptomeningeal and pre‐pontine enhancement, consistent with CSF dissemination, a pattern reported in several prior suprasellar cases [7]. A positive BRAF V600E result allowed dabrafenib and trametinib to be combined with carboplatin and vincristine. Bouffet et al. demonstrated in a randomized trial that this combination achieved a response rate of 47% versus 11% for chemotherapy alone, with a progression‐free survival of 20.1 versus 7.4 months, in pediatric low‐grade glioma with BRAF V600 mutations [10]. That trial enrolled DIA and DIG patients, making it directly relevant. The proposition that suprasellar disease behaves differently from hemispheric disease is supported by the available data but should be treated as a hypothesis. In the largest pooled series (Table 2), the suprasellar lesion progressed in 9 of 18 patients and 5 died over a median follow‐up of only 25 months [7]. However, location is confounded with extent of resection, which is the most consistently identified prognostic variable, so worse outcomes may reflect unresectability rather than intrinsic biology. A formal individual participant data meta‐analysis identified high Ki‐67 and multifocality, not location, as the variables associated with recurrence [6, 22]. The defensible statement is that suprasellar location is associated with worse reported outcomes, that this is plausibly explained by surgical inaccessibility, and that whether a genuine biological difference exists remains unresolved. TABLE 2Reported suprasellar and hypothalamic desmoplastic infantile ganglioglioma and astrocytoma, with the present case.ReportAgeSexPresenting featuresImaging of the suprasellar or hypothalamic lesionOther sitesExtent of resectionMolecular and key immunohistochemical findingsAdjuvant therapyOutcome (follow‐up)Setty et al. [14]4 monthsMMicrocephaly, nystagmusSuprasellar mass with metastases at presentationHypothalamus, posterior fossa, spinal canalBiopsy of the suprasellar lesionAnaplasia present; GFAP positive; tumor cells in ventricular CSFChemotherapyAlive with stable residual disease (38 months)Bock et al. [15]4 monthsMRaised intracranial pressureSuprasellar mass with diffuse leptomeningeal spreadDiffuse leptomeningesBiopsyAnaplasia absent; MAP2C positive; GFAP and S100 variable; p53 variableVincristine, cyclophosphamide, methotrexate, carboplatin, etoposideDied of progression (5 months)De Munnynck et al. [16]2 yearsFMacrocephaly, vomitingHypothalamic mass with pial and ependymal depositsRight hemisphere, pia, ependymaGross total resection of the hemispheric lesion; hypothalamic lesion observedAnaplastic component (35%); GFAP, synaptophysin, and NeuN positive; Ki‐67 45%Vincristine, carboplatinDied of progression (11 months)Darwish et al. [17]4 monthsMIrritability, failure to thrive, increasing head circumferenceSuprasellar mass; leptomeningeal and subarachnoid metastasesOutlet of the fourth ventricle, basal cisternsPartial resection and ventriculoperitoneal shuntAnaplasia absent; Ki‐67 1%–2%NoneDied of respiratory insufficiency and hypothalamic dysfunction (1 month)Abuharbid et al. [18]11 monthsFNystagmusSuprasellar massCerebellar vermis, spinal cordGross total resection of the vermian lesion; suprasellar lesion observedGFAP, MAP2, vimentin and S100 positive; BRAF V600E positive; Ki‐67 2%NoneAlive; suprasellar lesion progressed while spinal lesions regressed (16 months)Narayan et al. [19]8 monthsFMacrocephaly, regression of milestones, obstructive hydrocephalusMultifocal cranial and spinal disease involving the basal cisternsThalamus, cerebellum, parietal cortex, tentorium, leptomeninges, spinal cordVentriculoperitoneal shunt and excisional biopsy of a frontal lesionAnaplasia absent; Ki‐67 0.5%–1%; BRAF V600E negativeMultiple cycles of chemotherapyAlive but progressive; solid lesions regressed while cystic lesions progressed (12 months)Naylor et al., Case 1 [8]3 monthsFRapidly enlarging head circumference, nystagmus, bilateral optic atrophyLarge homogeneously enhancing solid mass without cystic component; hydrocephalusNoneSubtotal resectionDIA; IDH1 R132H negative; BRAF VE1 negative; H3K27me3 retained; INI1 retainedChemotherapy and whole‐brain radiotherapy (4500 cGy) with boostAlive; recurrence with cystic transformation requiring reoperation; visual impairment, hemiparesis, panhypopituitarism, developmental delay, epilepsy (9 years)Naylor et al., Case 2 [8]2 monthsMRapidly enlarging head circumference, downward gaze preferenceHomogeneously enhancing solid mass; hydrocephalusNonePartial resectionDIG; IDH1 R132H negative; BRAF VE1 negative; H3K27me3 lost; INI1 retainedNot statedAlive; visual impairment, developmental delay, multiple shunt procedures, seizures, diabetes insipidus (5 years)Naylor et al., Case 3 [8]4 monthsMRapidly enlarging head circumference, nystagmusHomogeneously enhancing solid mass; hydrocephalusNonePartial resectionDIG; IDH1 R132H negative; BRAF VE1 negative; H3K27me3 retained; INI1 retainedNot statedDied with tumor progression; visual impairment, panhypopituitarism, stroke (4 months)Wang et al., Case 2 [20]6 monthsMBilateral nystagmus, exophthalmosSolid and cystic suprasellar lesion; solid portion hypointense on T1 and T2Cavernous sinuses, hippocampus, intraorbital, cisterna magnaPartial resectionGFAP and OLIG2 positive; NeuN negative; p53 positive; ATRX lost; IDH1 negative; BRAF V600E positive; Ki‐67 5%NoneAlive; spontaneous regression of the suprasellar lesion (26 months)Shobini Vishali et al. [21]12 monthsNot statedIrritability, recurrent vomitingLarge suprasellar mass; T1 hypointense, T2, and FLAIR hyperintense, intense enhancementNoneExcision via frontal craniotomyDIA; GFAP positiveNot statedNot statedWang et al., Case 1 [7]85 monthsFNystagmusSolid; T1 hypointense, T2 isointense, heterogeneous enhancement, no edemaNoneSubtotal resectionIDH1 negative; GFAP, synaptophysin, NeuN, S100, and OLIG2 positiveNot statedAlive with stable residual disease; visual deficit (60 months)Wang et al., Case 2 [7]6 monthsMNystagmusSolid; T1 and T2 isointense, heterogeneous enhancement, marked edemaMultifocalPartial resectionBRAF V600E positive; GFAP, S100, and OLIG2 positive; NeuN negative; Ki‐67 5%Not statedAlive; spontaneous regression (26 months)Wang et al., Case 3 [7]12 monthsMDownward gazeSolid; T1 hypointense, T2 hyperintense, homogeneous enhancementNonePartial resectionGFAP, S100 and OLIG2 positive; synaptophysin and NeuN negative; Ki‐67 5%Not statedDied of malignant intracranial hypertension from progression and acute hydrocephalus (15 months)Wang et al., Case 4 [7]1 monthFSeizuresSolid; T1 and T2 isointense, heterogeneous enhancement, mild edemaNoneSubtotal resectionBRAF V600E wild type; GFAP, S100, and OLIG2 positive; Ki‐67 5%Not statedAlive with stable residual disease; visual deficit (24 months)Wang et al., Case 5 [7]2 monthsFSeizuresSolid; T1 and T2 isointense, heterogeneous enhancementNonePartial resectionBRAF V600E wild type; IDH1 negative; GFAP, S100, and OLIG2 positiveOral temozolomideAlive; spontaneous regression (41 months)Present case7 monthsFLeft‐beating gaze nystagmus, gross motor delay; no hydrocephalus2.9 cm solid and cystic mass; solid portion T1 isointense and T2 hyperintense with avid heterogeneous enhancement; chiasm, hypothalamus, and third ventricle involved; extension to right thalamus, basal ganglia and midbrain; no hydrocephalus, hemorrhage, restricted diffusion, or leptomeningeal enhancement at diagnosisNone at diagnosis; interval leptomeningeal and pre‐pontine enhancement during follow‐upPartial resectionDIG; BRAF V600E positive by VE1 immunohistochemistry; GFAP, S100, and OLIG2 positive; synaptophysin focally positive; NeuN, neurofilament protein, and chromogranin A negative; INI1 and ATRX retained; H3K27me3 lost; H3 K27M negative; Ki‐67 below 2%; sequencing not performedBRAF‐targeted therapy combined with chemotherapyAlive at 4 months; suprasellar residuum stable, new leptomeningeal and pre‐pontine enhancement suspicious for CSF dissemination, stable on combined BRAF‐targeted therapy and chemotherapy (4 months) Note: Cases reported only in pooled form, without individually extractable data, are not listed separately; the pooled series of 18 suprasellar patients is summarized in the text. Where a report described multifocal disease including a suprasellar or hypothalamic component, the extent of resection refers to the lesion actually operated upon, as indicated.Abbreviations: CSF, cerebrospinal fluid; DIA, desmoplastic infantile astrocytoma; DIG, desmoplastic infantile ganglioglioma; F, female; FLAIR, fluid‐attenuated inversion recovery; GFAP, glial fibrillary acidic protein; IDH1, isocitrate dehydrogenase 1; INI1, integrase interactor 1; M, male; MAP2, microtubule‐associated protein 2; NeuN, neuronal nuclear antigen; OLIG2, oligodendrocyte transcription factor 2. Reported suprasellar and hypothalamic desmoplastic infantile ganglioglioma and astrocytoma, with the present case. Note: Cases reported only in pooled form, without individually extractable data, are not listed separately; the pooled series of 18 suprasellar patients is summarized in the text. Where a report described multifocal disease including a suprasellar or hypothalamic component, the extent of resection refers to the lesion actually operated upon, as indicated. Abbreviations: CSF, cerebrospinal fluid; DIA, desmoplastic infantile astrocytoma; DIG, desmoplastic infantile ganglioglioma; F, female; FLAIR, fluid‐attenuated inversion recovery; GFAP, glial fibrillary acidic protein; IDH1, isocitrate dehydrogenase 1; INI1, integrase interactor 1; M, male; MAP2, microtubule‐associated protein 2; NeuN, neuronal nuclear antigen; OLIG2, oligodendrocyte transcription factor 2. Limitations Several limitations apply. BRAF V600E was demonstrated by immunohistochemistry alone; sequence‐level confirmation and DNA methylation profiling were not available, so the fifth‐edition WHO pathway for genetically unresolved lesions could not be completed. Only part of the tumor was examined, so a poorly differentiated component or a more convincing neuronal population elsewhere cannot be excluded, and the DIG versus DIA distinction is provisional. The suspicion of CSF dissemination rests on imaging rather than cytological proof, and reactive postoperative leptomeningeal enhancement cannot be entirely dismissed. Follow‐up is limited to 4 months, which is insufficient to establish the durability of disease control on MAPK pathway inhibition, and the radiological stability observed to date should not be interpreted as evidence of sustained efficacy. Conclusion A 7‐month‐old girl with nystagmus and developmental delay proved to have a suprasellar DIG, a location documented in only 18 previous patients. Four practical messages emerge. First, DIG/DIA belongs in the differential diagnosis of an infant suprasellar mass, and ocular signs in this setting should increase rather than decrease suspicion. Second, integrated morphological and immunohistochemical assessment can establish a desmoplastic glioneuronal tumor confidently on a deep partial specimen, though the DIG versus DIA distinction may remain provisional. Third, BRAF V600E testing should be regarded as a therapeutic investigation whenever gross total resection has not been achieved. Fourth, the apparently worse outcomes of suprasellar disease should be treated as a hypothesis confounded by unresectability, not as an established biological property, and argue for prolonged neuraxis surveillance rather than therapeutic pessimism. Author Contributions Tawfiq Zuhair Abdullah Allaylah: writing – original draft, writing – review and editing, supervision, visualization, conceptualization. Funding The author has nothing to report. Ethics Statement This study is a single‐patient case report. Ethical approval was not required for this case report according to the policy of our institution, as the manuscript describes a single patient and does not involve an interventional research protocol. Consent Written informed consent for publication of the clinical details and accompanying images was obtained from the patient's parent/legal guardian. All identifying information was removed, and the report has been prepared in an anonymous form to protect patient privacy. Conflicts of Interest The author declares no conflicts of interest. Acknowledgments AI Use Disclosure: The authors used an AI‐assisted writing tool only for language editing and organizational support. All clinical content, interpretation, literature selection, and final manuscript verification were performed by the authors, who take full responsibility for the accuracy and integrity of the work. Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. References Associated Data Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.